Skip to content

The role of the microbiome in pancreatic cancer personalized therapy prognosis

The role of the microbiome in pancreatic cancer personalized therapy prognosis - PDACmBiom

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00028995
Enrollment
300
Registered
2022-09-14
Start date
2024-10-10
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K80-K87

Interventions

Group 1: Comparison of stool and tissue microbiomes of pancreatitis and IPMN patients (serving as tumor precursors with and increased tumor risk) with the stool and tissue microbiome of patients with

Sponsors

Universitätsklinikum Heidelberg. Dept. Allgemeine, Viszerale und Transplantations Chirurgie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Pancreatic diseases (pancreatitis, IPMN, PDAC).

Exclusion criteria

Exclusion criteria: not pancreatic disease.

Design outcomes

Secondary

MeasureTime frame
Determination of risk bacteria strains in stool and/or tissue of pancreatitis and IPMN patients with increased pancreatic cancer risk.

Primary

MeasureTime frame
Determination of the fecal, and intra-tumoral microbiome in patients with tumor precursor lesions (pancreatitis and IPMN patients) and in pancreatic carcinoma patients. Stool samples from healthy volunteers and healthy pancreatic tissue from the transplantation programs will be used as microbiome controls. Comparisons will be made between the different bacterial strains (the microbiome) and the pancreatic cancer prognosis. Stool samples are collected just before surgery and tissue are collected during the surgery. Healthy volunteers serve as controls for the stool samples. Unused pancreatic tissue from the transplant program serves as control tissue. The respective microbiome will be determined by 16s sequencingon stool and tissue and compared to disease (pancreatitis, IPMN versus pancreatic cancer).

Countries

Germany

Contacts

Public ContactFranco Fortunato

Universitätsklinikum Heidelberg, Chirurgische Klinik, Sektion Chirurgische Forschung,

Franco.Fortunato@uni-heidelberg.de06221-56 38352

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026